Kodiak Sciences (NASDAQ:KOD) Sets New 1-Year High After Analyst Upgrade

Kodiak Sciences Inc. (NASDAQ:KOD)’s share price reached a new 52-week high during mid-day trading on Monday after Lifesci Capital raised their price target on the stock from $85.00 to $145.00. Lifesci Capital currently has an outperform rating on the stock. Kodiak Sciences traded as high as $64.57 and last traded at $64.57, with a volume of 4558251 shares traded. The stock had previously closed at $32.35.

Several other research firms have also recently weighed in on KOD. The Goldman Sachs Group initiated coverage on shares of Kodiak Sciences in a research note on Thursday, September 24th. They issued a “neutral” rating and a $36.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kodiak Sciences in a research report on Friday, July 10th. JPMorgan Chase & Co. upped their price objective on Kodiak Sciences from $56.00 to $66.00 and gave the company an “overweight” rating in a report on Monday, August 3rd. HC Wainwright raised their target price on Kodiak Sciences from $58.00 to $96.00 and gave the stock a “buy” rating in a research note on Monday. Finally, UBS Group raised their target price on Kodiak Sciences from $80.00 to $120.00 and gave the stock a “buy” rating in a research note on Monday. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Kodiak Sciences currently has an average rating of “Moderate Buy” and an average target price of $100.43.

More Kodiak Sciences News

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Positive Phase 3 DAYBREAK results: Zenkuda and tabirafusp-ted (KSI-501) met their primary endpoints in wet AMD, with efficacy reported as comparable to Regeneron’s established Eylea treatment. KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears
• Positive Sentiment: Regulatory filing approaching: Kodiak plans to submit a biologics license application for Zenkuda, moving the drug closer to possible approval and revenue generation. The global retinal-drug market could exceed $32 billion by the end of the decade. Kodiak Sciences Stock Pops After Eye-Disease Drugs Pass Key Trial
• Positive Sentiment: Analyst support strengthened: UBS raised its price target to $120 and Lifesci Capital raised its target to $145, both maintaining bullish ratings. HC Wainwright also increased its target to $96 and assigned a buy rating.
• Neutral Sentiment: High volatility and valuation uncertainty: KOD has reached a new 52-week high after a dramatic rally, so further gains may depend on detailed trial data, regulatory progress and the eventual commercial profile of the drugs.
• Negative Sentiment: Options activity signals hedging or bearish speculation: Traders purchased 21,273 put options, approximately 1,361% above typical daily volume. This does not establish a fundamental problem, but it highlights elevated expectations and downside-risk concerns.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. V Square Quantitative Management LLC purchased a new position in Kodiak Sciences during the 1st quarter valued at about $26,000. Westfuller Advisors LLC purchased a new stake in Kodiak Sciences during the first quarter worth about $26,000. EverSource Wealth Advisors LLC increased its stake in Kodiak Sciences by 1,221.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company’s stock worth $28,000 after purchasing an additional 916 shares during the period. KBC Group NV acquired a new stake in shares of Kodiak Sciences during the first quarter worth about $39,000. Finally, E Fund Management Co. Ltd. purchased a new position in shares of Kodiak Sciences in the second quarter valued at approximately $228,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Kodiak Sciences Price Performance

The company’s 50 day moving average price is $40.26 and its 200 day moving average price is $38.27. The firm has a market cap of $5.73 billion, a PE ratio of -21.75 and a beta of 2.18.

Kodiak Sciences (NASDAQ:KOD) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.96) by ($0.09). Sell-side analysts expect that Kodiak Sciences Inc. will post -3.89 earnings per share for the current fiscal year.

About Kodiak Sciences

Kodiak Sciences Inc (NASDAQ: KOD) is a biopharmaceutical company focused on developing therapies for retinal diseases and other conditions affecting the eye. The company’s research is centered on antibody biopolymer conjugates, a technology designed to extend the duration of action of biologic medicines in ocular tissues and potentially reduce the frequency of administration.

Its lead development program has been tarcocimab tedromer, also known as KSI-301, an anti-vascular endothelial growth factor (VEGF) therapy investigated for retinal vascular diseases, including diabetic macular edema, diabetic retinopathy and neovascular age-related macular degeneration.